Although the EXSCEL (Exenatide Study of Cardiovascular Events Lowering) study has reported a potential cardiovascular benefit of once-weekly extended-release exenatide, the primary endpoint did not reach statistical significance [ 101 ].
← all excerpts
Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.
1
—
—